Provided by Tiger Trade Technology Pte. Ltd.

Mesoblast

14.36
-0.5000-3.36%
Post-market: 14.34-0.0200-0.14%19:30 EDT
Volume:177.09K
Turnover:2.54M
Market Cap:1.84B
PE:-19.51
High:14.63
Open:14.63
Low:14.26
Close:14.86
52wk High:21.50
52wk Low:9.61
Shares:128.30M
Float Shares:78.65M
Volume Ratio:0.41
T/O Rate:0.23%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.7359
EPS(LYR):-0.8457
ROE:-18.22%
ROA:-6.16%
PB:3.21
PE(LYR):-16.98

Loading ...

Mesoblast Earnings Call: Ryoncil Momentum, Pipeline Upside

TIPRANKS
·
Mar 27

Mesoblast CEO Granted Additional Options Following Shareholder Approval

TIPRANKS
·
Mar 20

Mesoblast Issues 3.25 Million Unquoted Options Under Employee Incentive Scheme

TIPRANKS
·
Mar 20

Mesoblast Sets Inaugural R&D Day to Showcase Strategy, Ryoncil and Pipeline

TIPRANKS
·
Mar 18

Mesoblast Discloses Director Gregory George’s Share and ADS Purchases in Early March 2026

TIPRANKS
·
Mar 13

Dr. Teresa Montagut Appointed as Clinical Development and Medical Affairs Head at Mesoblast

GlobeNewswire
·
Mar 12

Mesoblast hires Regeneron veteran to lead clinical development and medical affairs

TIPRANKS
·
Mar 12

Mesoblast Director Gregory George Deepens Stake with US$16.4m Share Purchases

TIPRANKS
·
Mar 10

Cynata Therapeutics' Drug Candidate's Potential Reinforced by Mesoblast Results, Says Euroz Hartleys

MT Newswires Live
·
Mar 09

Analysts Offer Insights on Healthcare Companies: Neuren Pharmaceuticals Limited (OtherNURPF), Mesoblast Limited (OtherMEOBF) and Ramsay Health Care (OtherRMSYF)

TIPRANKS
·
Mar 02

Mesoblast Earnings Call: Ryoncil Momentum Meets Rising Costs

TIPRANKS
·
Feb 28

Mesoblast H1 EPS $(0.03) Beats $(0.20) Estimate, Sales $51.342M Miss $72.000M Estimate

Benzinga
·
Feb 27

BRIEF-Mesoblast Sees Full-Year Fiscal 2026 Ryoncil Net Revenue To Range Between $110 Million And $120 Million

Reuters
·
Feb 27

Press Release: Ryoncil(R) Profits Underpinning Substantial Growth Pipeline

Dow Jones
·
Feb 27

Mesoblast Updates Investors on 2025 Results and Operational Outlook

TIPRANKS
·
Feb 27

Mesoblast Files Form 6-K Providing Interim Financial and Risk Disclosures

TIPRANKS
·
Feb 27

Mesoblast Posts Narrower Fiscal H1 Loss, Higher Revenue

MT Newswires Live
·
Feb 27

Mesoblast Ltd - Sees Full-Year Fiscal 2026 Ryoncil Net Revenue to Range Between US$110 Million and US$120 Million

THOMSON REUTERS
·
Feb 27

Mesoblast Ltd - Hy Total Revenues $51.3 Mln

THOMSON REUTERS
·
Feb 27

Mesoblast Ltd expected to post a loss of 7 cents a share - Earnings Preview

Reuters
·
Feb 25